The intranasal esketamine EEG-microstate paper draws a published methodological critique flagging small-n/paired-design limits within 8 weeks.

The esketamine brain-wave study almost certainly used a small number of patients and compared each person to their own earlier results rather than to a separate control group. Studies designed this way reliably attract published criticism — in the form of letters or commentaries — pointing out that the results might not hold up in a larger, more rigorous test.

Rapid 24h biomarker claims in suicidal MDD invite scrutiny. Small-n paired designs reliably attract published critiques (letters, commentaries, or preprint responses) flagging statistical power and design confounds.